Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Nemirovsky

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Blood Cancer Journal|November 2, 2025
Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myelomaEric Jurgens, Tala Shekarkhand, Colin Rueda, et al.
Blood Cancer Journal|April 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myelomaHamza Hashmi, Tara Sebastian, Sridevi Rajeeve, et al.
Blood Cancer Journal|May 31, 2024
Comparison of infectious complications with BCMA-directed therapies in multiple myelomaKarthik Nath, Tala Shekarkhand, David Nemirovsky, et al.
Hemasphere|December 1, 2025
Patterns and safety of glucocorticosteroid use following CD19 CAR-T therapy for large B-cell lymphomaEfrat Luttwak, David Nemirovsky, Sean M Devlin, et al.
Blood Advances|March 6, 2025
Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up DosingCarlyn R Tan, Alice X Wang, David Nemirovsky, et al.
Blood Advances|May 2, 2025
Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple MyelomaBenjamin O Adegbite, Carlyn Rose Tan, Tala Shekarkhand, et al.
JAMA Oncology|May 15, 2025
Barriers to Chimeric Antigen Receptor T-Cell TherapyYannis K Valtis, Kuo-Kai Chin, David Nemirovsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenanceRoss S Firestone, Anish K Simhal, Devin McAvoy, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Robust CD4<sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelEric M Jurgens, Sneha Mitra, Kevin Herrera, et al.
Blood Advances|May 4, 2023
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemiaJoseph G W McCarter, David Nemirovsky, Christopher A Famulare, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Blood Cancer Journal|November 2, 2025
Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myelomaEric Jurgens, Tala Shekarkhand, Colin Rueda, et al.
Blood Cancer Journal|April 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myelomaHamza Hashmi, Tara Sebastian, Sridevi Rajeeve, et al.
Blood Cancer Journal|May 31, 2024
Comparison of infectious complications with BCMA-directed therapies in multiple myelomaKarthik Nath, Tala Shekarkhand, David Nemirovsky, et al.
Hemasphere|December 1, 2025
Patterns and safety of glucocorticosteroid use following CD19 CAR-T therapy for large B-cell lymphomaEfrat Luttwak, David Nemirovsky, Sean M Devlin, et al.
Blood Advances|March 6, 2025
Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up DosingCarlyn R Tan, Alice X Wang, David Nemirovsky, et al.
Blood Advances|May 2, 2025
Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple MyelomaBenjamin O Adegbite, Carlyn Rose Tan, Tala Shekarkhand, et al.
JAMA Oncology|May 15, 2025
Barriers to Chimeric Antigen Receptor T-Cell TherapyYannis K Valtis, Kuo-Kai Chin, David Nemirovsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenanceRoss S Firestone, Anish K Simhal, Devin McAvoy, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Robust CD4<sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelEric M Jurgens, Sneha Mitra, Kevin Herrera, et al.
Blood Advances|May 4, 2023
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemiaJoseph G W McCarter, David Nemirovsky, Christopher A Famulare, et al.
Pageof 4